This HTML5 document contains 105 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/national-drug-code-directory/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n17http://linked.opendata.cz/resource/drugbank/mixture/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/chemspider/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/chebi/
n16http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n29http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/wikipedia/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/pharmgkb/
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n21http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/pubchem-compound/
n23http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00979/identifier/drugbank/
n11http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00979
rdf:type
n3:Drug
n3:description
A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. [PubChem]
n3:dosage
n12:271B485B-363D-11E5-9242-09173F13E4C5 n12:271B4857-363D-11E5-9242-09173F13E4C5 n12:271B4858-363D-11E5-9242-09173F13E4C5 n12:271B4859-363D-11E5-9242-09173F13E4C5 n12:271B485A-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# "Link":http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202173.html
n3:group
approved
n3:indication
Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.
n3:manufacturer
n5:271B4848-363D-11E5-9242-09173F13E4C5 n5:271B4849-363D-11E5-9242-09173F13E4C5 n5:271B484C-363D-11E5-9242-09173F13E4C5 n5:271B484D-363D-11E5-9242-09173F13E4C5 n5:271B484A-363D-11E5-9242-09173F13E4C5 n5:271B484B-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00979 n16:DB00979
dcterms:title
Cyclopentolate
adms:identifier
n19:0065-0395-15 n20:C06932 n21:2905 n22:46504517 n25:2802 n26:DB00979 n27:4024 n28:PA164743019 n29:Cyclopentolate
n3:mechanismOfAction
By blocking muscarinic receptors, cyclopentolate produces dilatation of the pupil (mydriasis) and prevents the eye from accommodating for near vision (cycloplegia).
n3:packager
n5:271B4847-363D-11E5-9242-09173F13E4C5 n5:271B4844-363D-11E5-9242-09173F13E4C5 n5:271B4845-363D-11E5-9242-09173F13E4C5 n5:271B4842-363D-11E5-9242-09173F13E4C5 n5:271B4843-363D-11E5-9242-09173F13E4C5 n5:271B4840-363D-11E5-9242-09173F13E4C5 n5:271B4841-363D-11E5-9242-09173F13E4C5 n5:271B483E-363D-11E5-9242-09173F13E4C5 n5:271B483F-363D-11E5-9242-09173F13E4C5 n5:271B483C-363D-11E5-9242-09173F13E4C5 n5:271B483D-363D-11E5-9242-09173F13E4C5 n5:271B483B-363D-11E5-9242-09173F13E4C5 n5:271B4846-363D-11E5-9242-09173F13E4C5
n3:synonym
β-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate Cyclopentolatum (+-)-Cyclopentolate (±)-cyclopentolate α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester Ciclopentolato Cyclopentolate alpha-(1-Hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester 2-(dimethylamino)Ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate 2-Phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester 1-Hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester beta-(dimethylamino)Ethyl (1-hydroxycyclopentyl)phenylacetate beta-Dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate 2-(dimethylamino)Ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate
n3:toxicity
Oral LD<sub>50</sub> in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.
n9:hasAHFSCode
n10:52-24-00
n3:mixture
n17:271B483A-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Treves, G.R.; US. Patent 2,554,511; May 29,1951; assigned to Schieffelin & Co.
n23:hasConcept
n24:M0005484
foaf:page
n8:cyclopentolate.html
n3:IUPAC-Name
n4:271B4860-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4866-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4865-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4862-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4863-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4864-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B485E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4877-363D-11E5-9242-09173F13E4C5 n4:271B485C-363D-11E5-9242-09173F13E4C5 n4:271B485F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B485D-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n11:S01FA04
n3:H-Bond-Acceptor-Count
n4:271B486C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B486D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4867-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4868-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B486A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4869-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B486B-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed following ophthalmic administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
512-15-2
n3:category
n3:containedIn
n15:271B4855-363D-11E5-9242-09173F13E4C5 n15:271B4856-363D-11E5-9242-09173F13E4C5 n15:271B4853-363D-11E5-9242-09173F13E4C5 n15:271B4854-363D-11E5-9242-09173F13E4C5 n15:271B4851-363D-11E5-9242-09173F13E4C5 n15:271B4852-363D-11E5-9242-09173F13E4C5 n15:271B484F-363D-11E5-9242-09173F13E4C5 n15:271B4850-363D-11E5-9242-09173F13E4C5 n15:271B484E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4872-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4874-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4875-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4876-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4871-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4870-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4873-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4861-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B486E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B486F-363D-11E5-9242-09173F13E4C5